Preliminary economic evaluation of biopharming in New Zealand

Abstract

From the academic literature, this report derives an economic model or framework for considering biopharming. This model is based on a cost-benefit approach to valuing changes in products and production methods. The model indicates the product dimensions that are likely to be affected by biopharming methods and how these dimensions may affect the costs and benefits of production. It also identifies the uncertainties in existing analyses. Finally, it demonstrates a method by which careful analysis of the economic costs and benefits of biopharming could proceed. Two potential products are discussed using this model: recombinant human lactoferrin (rhLF) produced in cow’s milk and low-GI potatoes.